New cancer shot shows promise: real-world study launched for advanced tumors
NCT ID NCT07562347
First seen May 03, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study will track 120 adults with advanced solid tumors who receive envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. Researchers want to see how well it controls tumors and what side effects occur in everyday medical practice. The goal is to confirm early findings that this drug can shrink tumors in about 45% of patients with certain genetic markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.